|
|
 |
|
Viewing report
|
|
|
|
The Cancer Market Outlook to 2009
Business Insights, Sep 2004, Pages: 268
The NEW management report ‘The Cancer Market Outlook to 2009’, published October 2004, quantifies the patient potential in different cancer sub-markets and provides benchmarks for new cancer drug development and marketing strategies. This report identifies key areas of unmet need and profiles the market leading products of the future. The global cancer market is characterized by a mix of established gold standard therapies and new innovative products rapidly capturing market share. While a number of blockbuster therapies lose patent protection, heavy R&D investment has resulted in 400 potential new drugs currently progressing through clinical trials. Significant unmet needs and high incidence of disease continue to drive market growth, leaving a number of companies competing to improve treatment efficacy and drive market share. Use this report to quantify patient potential in cancer sub-markets, benchmark your portfolio against the eight leading companies in the sector and devise strategies to counter threats to your market position in the next five years.
Key findings of the report
- The global cancer market is forecast to grow from $38.5bn in 2003 to $53.1bn in 2009, representing an average annual growth rate of 5.49%.
- In the US alone, it is predicted that 217,000 new cases of breast cancer will be diagnosed in 2004. Although mortality is decreasing and the disease is relatively well understood, significant unmet needs exist.
- The total adjunct therapy market was valued at $16.0bn in 2003, a 18.2% increase on 2002 sales. Market growth was driven by the strong sales performance of the new generation HGF products, in particular Amgen's Aranesp (darbepoietin) and Neulasta (pegfilgrastim).
- In 2003, BMS maintained its position as the leading player in the cancer market with total oncology sales of $4.1bn equating, to a 10.6% market share.
- The innovative cancer therapy class is forecast to almost double in value during the forecast period, from $6.4bn in 2003 to 12.5bn in 2009, by which time it will overtake the cytotoxic drug classes in value terms.
The answers to your questions
- What will the key areas of growth in the cancer market be in the next 5 years?
- What are the key unmet needs in the global cancer market?
- What is the most effective drug launch and brand building strategy in each different cancer treatment setting?
- What will the leading blockbusters of the future be in the global cancer market?
- What impact will key patent expiries and the launch of generic products have on the global cancer market?
- What impact will the launch of new angiogenesis inhibitors and other novel therapies have on the cancer market?
Why you should order your copy today
Benchmark the performance of competing products by indication, drug class and marketing company.
Determine the impact of patent expiry on major gold standard products, including Nolvadex, Intron A and Lupron.
Examine the strategic implications of industry developments for established or recently approved therapies, including
AstraZeneca's Iressa, Millennium's Velcade and Corixa and GSK's Bexxar.
Evaluate the latest regulatory implications on future drug marketing policy and drug development.
Understand the benefits of developing drugs initially for niche indications, thereby avoiding the greater competition and more rigorous regulatory process associated with drug development for more prevalent cancers.
Identify strategies used to position product franchises of both established players and new entrants.
Customers who bought this item also bought
The Cancer Market Outlook to 2012
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Drug Delivery Technology - Revolutionizing Cancer Therapies
Commercial Insight: Antihormonal Cancer Therapies
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
The Cancer Market Outlook to 2008
Cancer Therapies - Global Strategic Business Report
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
Forecast Insight: Top 20 Cancer Therapy Brands
Cancer Therapies - Global Market Opportunities
Cancer Therapies - Global Market Opportunities
Drug Delivery in Cancer - Technologies, Markets and Companies
|
|
|
|
